Biblio

Export 2446 results:
Author [ Title(Desc)] Type Year
Filters: First Letter Of Keyword is A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
R. E. Kennedy, Cutter, G. R., Wang, G., and Schneider, L. S., Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials., J Alzheimers Dis, vol. 50, no. 4, pp. 1205-15, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation., J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation., J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation., J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation., J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation., J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
Y. - Y. Huang, Chen, S. - D., Leng, X. - Y., Kuo, K., Wang, Z. - T., Cui, M., Tan, L., Wang, K., Dong, Q., and Yu, J. - T., Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management., J Alzheimers Dis, vol. 86, no. 3, pp. 983-999, 2022.
F. K. Kok, van Leerdam, S. L., and de Lange, E. C. M., Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology., J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
F. K. Kok, van Leerdam, S. L., and de Lange, E. C. M., Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology., J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
F. K. Kok, van Leerdam, S. L., and de Lange, E. C. M., Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology., J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
S. X. Naughton, Raval, U., and Pasinetti, G. M., Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies., J Alzheimers Dis, vol. 76, no. 1, pp. 21-25, 2020.
S. X. Naughton, Raval, U., and Pasinetti, G. M., Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies., J Alzheimers Dis, vol. 76, no. 1, pp. 21-25, 2020.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial., J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial., J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial., J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial., J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
G. Zhang, Zhang, Y., Shen, Y., Wang, Y., Zhao, M., and Sun, L., The Potential Role of Ferroptosis in Alzheimer's Disease., J Alzheimers Dis, vol. 80, no. 3, pp. 907-925, 2021.
G. Zhang, Zhang, Y., Shen, Y., Wang, Y., Zhao, M., and Sun, L., The Potential Role of Ferroptosis in Alzheimer's Disease., J Alzheimers Dis, vol. 80, no. 3, pp. 907-925, 2021.
Q. Tao, Zhu, H., Chen, X., Stern, R. A., Kowall, N., Au, R., Blusztajn, J. Krzysztof, and Qiu, W. Qiao, Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease., J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
Q. Tao, Zhu, H., Chen, X., Stern, R. A., Kowall, N., Au, R., Blusztajn, J. Krzysztof, and Qiu, W. Qiao, Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease., J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
Q. Tao, Zhu, H., Chen, X., Stern, R. A., Kowall, N., Au, R., Blusztajn, J. Krzysztof, and Qiu, W. Qiao, Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease., J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
Q. Tao, Zhu, H., Chen, X., Stern, R. A., Kowall, N., Au, R., Blusztajn, J. Krzysztof, and Qiu, W. Qiao, Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease., J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
D. E. Bredesen, Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C., Boyd, A., Hill, B. D., Hausman-Cohen, S., Attarha, M., Chwa, W. Jong, Kurakin, A., and Jarrett, M., Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications., J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
J. Zhou, Gennatas, E. D., Kramer, J. H., Miller, B. L., and Seeley, W. W., Predicting regional neurodegeneration from the healthy brain functional connectome., Neuron, vol. 73, no. 6, pp. 1216-27, 2012.
J. Zhou, Gennatas, E. D., Kramer, J. H., Miller, B. L., and Seeley, W. W., Predicting regional neurodegeneration from the healthy brain functional connectome., Neuron, vol. 73, no. 6, pp. 1216-27, 2012.

Pages